Bart Henderson
Founder at Torque Therapeutics, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
David Meeker | M | 69 | 9 years | |
John Cox | M | 61 |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | 5 years |
Samuel Cohen | M | 38 |
Wavebreak Therapeutics Ltd.
Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | 8 years |
Christophe Jean | M | 67 | 9 years | |
Bruce Sachs | M | 64 | 26 years | |
Douglas Cole | M | 63 |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | 9 years |
George Martin | M | 65 |
Wavebreak Therapeutics Ltd.
Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | 6 years |
David McGirr | M | 69 | 9 years | |
Ed Mathers Mathers | M | 64 | 11 years | |
Christopher Dobson | M | 75 |
Wavebreak Therapeutics Ltd.
Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | 8 years |
Michele Vendruscolo | F | 58 |
Wavebreak Therapeutics Ltd.
Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | 8 years |
Douglas A. Lauffenburger | M | - |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | 8 years |
Owen Hughes | M | 49 |
Wavebreak Therapeutics Ltd.
Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | 6 years |
Andrew von Eschenbach | M | 82 |
Wavebreak Therapeutics Ltd.
Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | 5 years |
Fiona Dunlevy | F | 41 |
Wavebreak Therapeutics Ltd.
Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | - |
Lisa Butterfield | F | - |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Keith Gottesdiener | M | 70 | 9 years | |
Charlie Sanders | M | 91 | 14 years | |
Elizabeth Stoner | M | 73 | - | |
Elaine S. Ullian | F | 76 | 22 years | |
Richard H. Aldrich | M | 69 | 12 years | |
Thomas Auchincloss | M | 62 | 7 years | |
Jonathan Silverstein | M | 57 | - | |
Todd Foley | M | 52 | 7 years | |
Alastair Garfield | M | - | 4 years | |
Julius Knowles | M | 61 | 2 years | |
Julie Krop | M | 57 | 14 years | |
Mark Namchuk | M | - | 13 years | |
Fred Fiedorek | M | 69 | 4 years | |
Christian de la Tour | M | 64 | - | |
Thierry Hercend | M | - | 4 years | |
Wei Li | M | 52 | 3 years | |
Michael Partridge | M | - | - | |
Neil Exter | M | 65 | 5 years | |
Kenneth S. Boger | M | 77 | - | |
Stephen H. Watkins | M | - | 2 years | |
Manuel A. Navia | M | 77 | 8 years | |
Johanna Messina-Power | F | 51 | 9 years | |
John Alam | M | 62 | 11 years | |
Sarah Cecil | F | 72 | 9 years | |
Jim Murray | M | - | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 34 | 82.93% |
United Kingdom | 7 | 17.07% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Bart Henderson
- Personal Network